First-line maintenance therapy with Bavencio (avelumab) significantly delays disease progression or death in people with inoperable, locally advanced or metastatic urothelial carcinoma, a common type of bladder cancer, according to interim data from a Phase 3 trial. This survival benefit was observed regardless of the levels of the PD-L1 protein in cancer cells (the therapy’s target), highlighting that Bavencio may be effective in treating advanced bladder cancer patients who achieve at least disease stabilization after first-line platinum-based chemotherapy.…
You must be logged in to read/download the full post.
The post Bavencio Shows Benefit as 1st-line Maintenance Therapy for Bladder Cancer in Phase 3 Trial appeared first on BioNewsFeeds.